Official Course Description: MCCCD Approval: 06/17/03
DMI271 20036-20062	LEC	3 Credit(s)	3 Period(s)
Nuclear Medicine Imaging II
Endocrine/exocrine, gastrointestinal/accessory organ, and hematological and in vitro nuclear medicine imaging. Review of related body system anatomy, physiology and pathology. Endocrine/exocrine studies to include thyroid uptake, thyroid scan, parathyroid imaging, adrenal imaging, and lacrimal duct imaging. Gastrointestinal/accessory organ studies to include salivary gland, esophageal motility/transit and reflux, gastric emptying, helicobacter pylori detection, liver/spleen imaging, hemangima detection, hepatobiliary imaging, gastrointestinal hemorrhage, Meckel's diverticulum, Le Veen Shunt, and intrahepatic pump study. Hematological and in vitro studies to include bone marrow imaging, Schillings test, plasma volume, red cell mass, total blood volume, T- cell survival, splenic imaging and radioassay. Prerequisites: DMI267 or permission of Nuclear Medicine Technology program director.

Go to Competencies    Go to Outline
 

MCCCD Official Course Competencies:
DMI271   20036-20062	Nuclear Medicine Imaging II

1.	Discuss the gross anatomy and physiology of the endocrine/exocrine, gastrointestinal/accessory organ and hematological systems as they relate to nuclear medicine studies. (I, VIII, XXI)
2.	Describe the characteristics and causes of common pathologies of the endocrine/exocrine, gastrointestinal/accessory organ and hematological systems related to nuclear medicine procedures including susceptible populations and potential treatments. (II, IX, XXII)
3.	List the indications for performing selected endocrine/exocrine, gastrointestinal/accessory organ, hematological and in vitro studies. (III-VII, XXIII-XXIX)
4.	Discuss why a nuclear medicine study would be preferable to or compliment other diagnostic modalities in various cases. (III-VII, XXIII-XXIX)
5.	Describe the radiopharmaceuticals used for endocrine/exocrine, gastrointestinal/accessory organ, hematological and in vitro studies including the physical and chemical properties, biorouting dose preparation, and route and method of administration. (III-VII, XXIII-XXIX)
6.	Specify the dose range for endocrine/exocrine, gastrointestinal/accessory organ, hematological and in vitro studies and the resulting radiation doses to various organs and tissues. (III-VII, XXIII-XXIX)
7.	Describe patient preparation for selected endocrine/exocrine, gastrointestinal/accessory organ, hematological and in vitro studies. (III-VII, XXIII-XXIX)
8.	Describe the procedures for selected endocrine/exocrine, gastrointestinal/accessory organ, hematological and in vitro studies including equipment, protocol, dose, administration technique, administration-to-acquisition times, acquisition parameters, standard positioning, special imaging adaptations, data processing and potential pitfalls. (III- VII, XXIII-XXIX)
9.	Recognize the normal distribution, normal variants and various artifacts seen on selected endocrine/exocrine, gastrointestinal/accessory organ, hematological and in vitro imaging studies and printed images. (III-VII, XXIII-XXIX)
10.	Describe possible sources of error in selected endocrine/exocrine, gastrointestinal/accessory organ, hematological and in vitro studies. (III, XXV, XXVI, XXVII, XXVIII)
11.	Discuss the diagnostic and prognostic value of selected endocrine/exocrine, gastrointestinal/accessory organ, hematological and in vitro studies. (III-VII, XXIII-XXIX)
12.	Discuss common causes of false-negative and false-positive thyroid uptake results. (III-VII, XXIII-XXIX)
13.	Describe the interventional procedures that may be used for selected endocrine/exocrine, gastrointestinal/accessory organ, hematological and in vitro studies. (X, XI, XVI, XVIII)
14.	Describe the appearance of various pathologies seen on selected endocrine/exocrine, gastrointestinal/accessory organ, hematological and in vitro imaging studies and printed images. (X-XX, XXV-XXIX)
15.	Discuss kit and dose preparation and special precautions taken to assure quality of endocrine/exocrine, gastrointestinal/accessory organ, hematological and in vitro study agents. (XI-XVIII)
16.	Describe special radiation safety precautions considered when performing selected endocrine/exocrine, gastrointestinal/accessory organ, hematological and in vitro studies. (XI, XII, XIII)
17.	Calculate esophageal transit and emptying times and percent esophageal reflux and emptying. (XI)
18.	Describe the process for tagged red blood cells for hemangioma detection. (XV)
19.	Identify structures on hemangioma detection single photon emission computed tomography (SPECT) slices. (XV)
20.	Calculate gall bladder ejection fraction. (XVI)
21.	Describe the process for tagged red blood cells for GI bleeding scan. (XVIII)
22.	Describe dose and standard preparation for a Schilling test. (XXIV)
23.	Calculate Schilling test results, plasma volume, red cell mass, total blood volume, and degree of red cell sequestration for selected hematological studies. (XXIV- XXVIII)
24.	Describe the preparation of the standard used to calculate a plasma volume. (XXV)
25.	Describe the procedures for plasma volume study including equipment, protocol, dose, administration technique, sample collection and processing, data processing and potential pitfalls. (XXV)
26.	Describe the procedure for correcting for a vascular leakage when performing a plasma volume determination. (XXV)
27.	Determine the normal range of plasma volume values red cell mass for a specific patient. (XXV, XXVI)
28.	State the rationale for using the hematocrit correction factor when calculating the red cell mass. (XXV)
29.	Describe standard preparation and method for tagging red blood cells for red cell sequestration determination including the function of the components used tin the process. (XXVIII)
30.	Describe standard preparation and method for tagging and denaturing red blood cells for selective spleen imaging. (XXIX)
31.	Describe the characteristics of a good assay for detecting minute quantities of substances in the blood. (XXX)
32.	Describe the basic process for competitive and direct method radioassay including the data reduction process. (XXX)
33.	Explain how the law of mass action and the concept of equilibrium apply to competitive radioassay. (XXX)
34.	Describe quality control methods used to evaluate assays, curves, and various data including control solutions, curve analysis, standard deviation, coefficient of variation, and Levy-Jenning plots. (XXX)

Go to Description    Go to top of Competencies
 

MCCCD Official Course Outline:
DMI271   20036-20062	Nuclear Medicine Imaging II

I. Review of Endocrine/Exocrine Anatomy and Physiology A. Gross structure and function of glands B. Cellular anatomy and functio II. Review of Endocrine/Exocrine Pathology A. Thyroid B. Parathyroid C. Adrenal D. Lacrimal duct obstruction III. Thyroid Uptake Study A. Indications B. Radiopharmaceuticals 1. Tracers 2. Physical and chemical characteristics 3. Radiopharmaceutical preparation 4. Dose range and route of administratioin 5. Diorouting 6. Dosimetry D. Contraindications and adverse reactions E. Equipment F. Basic procedures and processing G. Interpretation of data H. Normal range I. Normal variants J. Abnormal K. Sources of error L. Diagnostic/Prognostic Value of the Study IV. Thyroid Scan A. Indications B. Radiopharmaceuticals 1. Tracers 2. Physical and chemical characteristics 3. Radiopharmaceutical preparation 4. Dose range and route of administration 5. Biorouting 6. Dosimetry C. Contraindications and adverse reactions 1. Physical conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparations E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and processing 1. Protocols 2. Dose range and administration technique 3. Acquisition parameters 4. Positioning and views, including adaptations 5. Image formatting 6. Pitfalls G. Interpretation of images 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors based on diagnosis V. Parathyoid Imaging A. Indications B. Radiopharmaceuticals 1. Tracers a. Tc-99m sestamibi b. Tc-99m sestamibi/I-123 sodium iodide c. Tc099m sestamibi/Tl-201 thallous chloride d. Tc099m pertechnetate/Tl-201 thallous chloride 2. Physical and chemical characteristics 3. Radiopharmaceutical preparation 4. Dose range and route of administration 5. Biorouting 6. Dosimetry C. Contraindications and adverse reactions 1. Physical conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and processing 1. Protocols 2. Dose range and administration technique 3. Acquisition parameters 4. Positioning and views, including adaptations 5. Image formatting 6. Pitfalls G. Interpretation of images 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors based on diagnosis VI. Adrenal Imaging A. Indications B. Radiopharmaceuticals 1. Tracers a. I-123 MIBG (metaiodobenzylguanidine) b. I-131 MIBG c. I-131 norcholestrol 2. Physical and chemical characteristics 3. Radiopharmaceutical preparation 4. Dose range and route of administration 5. Biorouting 6. Dosimetry C. Contraindications and adverse reactions 1. Physical conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and processing 1. Protocols 2. Dose range and administration technique 3. Acquisition parameters 4. Positioning and views, including adaptations 5. Image formatting 6. Pitfalls G. Interpretation of images 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors based on diagnosis VII. Lacrimal Duct Imaging (Dacryoscintigraphy) A. Indications B. Radiopharmaceuticals 1. Tracer: Tc-99m pertechnetate 2. Physical and chemical characteristics 3. Radiopharmaceutical preparation 4. Dose range and route of administration 5. Biorouting 6. Dosimetry C. Contraindications and adverse reactions 1. Physical conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and processing 1. Protocols 2. Dose range and administration technique 3. Acquisition parameters 4. Positioning and views, including adaptations 5. Image formatting 6. Pitfalls G. Interpretation of images 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors based on diagnosis VIII. Gastrointestinal/Accessory Organ Review of Anatomy and Physiology A. Gross anatomy and physiology B. Cellular anatomy and function C. Blood flow D. Bile production IX. Review of Gastrointestinal/Accessory Organ Pathology A. Primary and metastatic neoplasms B. Salivary gland disorders 1. Sjogren's disease 2. Warthin's tumor 3. Obstruction 4. Space occupying C. Disorders of the esophagus 1. Gastroesophageal reflux disease 2. esophagitis 3. achalasia 4. scleroderma 5. Barrett's esophagus D. Gastric disorders 1. delayed emptying 2. "dumping" syndrome 3. peptic ulcer E. Liver and gallbladder 1. infections 2. circulatory disorders 3. cirrhosis 4. cholecystitis 5. cholelithiasis 6. congenital abnormalities 7. tumors a. primary b. metastatic c. hemangioma 8. Budd-Chiari syndrome F. Splenic disease 1. splenomegaly 2. space occupying lesions 3. asplenia 4. accessory spleen G. Gastrointestinal (GI) Hemorrhage H. Meckel's diverticulum X. Salivary Gland Imaging A. Indications B. Radiopharmaceuticals 1. Tracers a. I-123 MIBG (metaiodobenzylguanidine) b. I-131 MIBG c. I-131 norcholestrol 2. Physical and chemical characteristics 3. Radiopharmaceutical preparation 4. Dose range and route of administration 5. Biorouting 6. Dosimetry C. Contraindications and adverse reactions 1. Physical conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and processing 1. Protocols 2. Dose range and administration technique 3. Acquisition parameters 4. Positioning and views, including adaptations 5. Image formatting 6. Pitfalls G. Interpretation of images 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors based on diagnosis XI. Esophageal Motility/Transit and Reflux A. Indications B. Radiopharmaceuticals 1. Tracer: Tc-99m sulfur colloid (SC) 2. Physical and chemical characteristics 3. Kit and radiopharmaceutical preparation 4. Dose range and route of administration 5. Biorouting a. distribution b. excretion 6. Dosimetry C. Contraindications and adverse reactions 1. Physical and pathologic conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Special radiation safety considerations E. Patient preparation F. Equipment 1. camera 2. collimators 3. computer G. Basic procedure and processing 1. Protocols 2. Dose range and administration technique 3. Acquisition parameters 4. Positioning and views, including adaptations a. motility and transit b. reflux c. pumonary 5. Data processing 6. Image formatting 7. Pitfalls H. Interventions and procedures I. Interpretation of images and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors based on diagnosis XII. Gastric Emptying A. Indications B. Radiopharmaceuticals 1. Tracers a. Tc-99m sulfur colloid (solid) b. In-111DTPA (liquid) 2. Physical and chemical characteristics 3. Kit and radiopharmaceutical preparation 4. Dose range and route of administration 5. Biorouting a. distribution b. excretion 6. Dosimetry C. Contraindications and adverse reactions 1. Physical and pathologic conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Special radiation safety considerations E. Patient preparation F. Equipment 1. camera 2. collimators 3. computer G. Basic procedure and processing 1. Protocols 2. Dose range and administration technique 3. Acquisition parameters 4. Positioning and views, including adaptations 5. Data processing 6. Image formatting 7. Pitfalls H. Interpretation of images and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic risk factors based on diagnosis a. outcomes b. treatment decisions c. prognostic risk factors based on diagnosis XIII. Helicobacter Pylori Detection A. Indications B. Radiopharmaceutical 1. Carbon-14 labeled area 2. Physical characteristics 3. Kit and radiopharmaceutical preparation 4. Dose range and route of administration 5. Biorouting a. distribution b. excretion 6. Dosimetry C. Contraindications and adverse reactions 1. Physical and pathologic conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Special radiation safety considerations E. Patient preparation F. Equipment 1. camera 2. collimators 3. computer G. Basic procedure and processing 1. Protocols 2. Dose range and administration technique 3. Acquisition parameters 4. Positioning and views, including adaptations 5. Data processing 6. Image formatting 7. Pitfalls H. Interpretation of images and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic risk factors based on diagnosis a. outcomes b. treatment decisions c. prognostic risk factors based on diagnosis XIV. Liver/Spleen A. Indications B. Radiopharmaceutical 1. Tc-99 sulfur colloid 2. Physical characteristics 3. Kit and radiopharmaceutical preparation 4. Dose range and route of administration 5. Biorouting a. distribution b. excretion 6. Dosimetry C. Contraindications and adverse reactions 1. Physical and pathologic conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment 1. collimators 2. computer F. Basic procedure and processing 1. Protocols 2. Dose range and administration technique 3. Acquisition parameters G. Interpretation of images and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic risk factors based on diagnosis a. outcomes b. treatment decisions c. prognostic risk factors based on diagnosis XV. Hemangioma Detection A. Indications B. Radiopharmaceuticals 1. Tracers a. Tc-99m labeled red blood cells b. Tc-99m sulfur colloid 2. Physical and chemical characteristics 3. Kit and radiopharmaceutical preparation 4. Dose range and route of administration 5. Biorouting a. uptake b. distribution c. excretion 6. Dosimetry C. Contraindications and adverse reactions 1. Physical and pathologic conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and processing 1. Protocols 2. Dose range and administration technique 3. Acquisition parameters 4. Positioning and views, including adaptations 5. Data processing 6. Image formatting 7. Pitfalls G. Interpretation of images and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic risk factors based on diagnosis a. outcomes b. treatment decisions c. prognostic risk factors based on diagnosis XVI. Hepatobiliary Imaging A. Indications B. Radiopharmaceuticals 1. Tc-99m IDA (iminodiacetic acid) derivatives (ex.Tc-99m disofenin) 2. Physical and chemical characteristics 3. Kit and radiopharmaceutical preparation 4. Dose range and route of administration 5. Biorouting a. uptake b. distribution c. excretion 6. Dosimetry C. Contraindications and adverse reactions 1. Physical and pathologic conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and processing 1. Protocols 2. Dose range and administration technique 3. Acquisition parameters 4. Positioning and views, including adaptations 5. Data processing 6. Image formatting 7. Pitfalls G. Intervention and procedures 1. morphine enhanced 2. cholecystokinin intervention 3. quantitation (gallbladder ejection fraction) H. Interpretation of images and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic risk factors based on diagnosis a. outcomes b. treatment decisions c. prognostic risk factors based on diagnosis XVII. GI Hemorrhage A. Indications B. Radiopharmaceuticals 1. Tracers a. Tc-99m sulfur colloid b. Tc-99m labeled red blood cells 2. Physical and chemical characteristics 3. Radiopharmaceutical preparation 4. Dose range and route of administration 5. Biorouting a. uptake b. distribution c. excretion 6. Dosimetry C. Contraindications and adverse reactions 1. Physical and pathologic conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and processing 1. Protocols 2. Dose range and administration technique 3. Acquisition parameters 4. Positioning and views, including adaptations 5. Data processing 6. Image formatting 7. Pitfalls G. Interpretation of images and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic risk factors based on diagnosis a. outcomes b. treatment decisions c. prognostic risk factors based on diagnosis XVIII. Meckel's diverticulum A. Indications B. Radiopharmaceuticals 1. Tc-99m pertechnetate 2. Physical and chemical characteristics 3. Radiopharmaceutical preparation 4. Dose range and route of administration 5. Biorouting a. uptake b. distribution c. excretion 6. Dosimetry C. Contraindications and adverse reactions 1. Physical and pathologic conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and processing 1. Protocols 2. Dose range and administration technique 3. Acquisition parameters 4. Positioning and views, including adaptations 5. Data processing 6. Image formatting 7. Pitfalls G. Interventions and procedures 1. glucagon 2. cimetidine 3. pentagastrin H. Interpretation of images and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic risk factors based on diagnosis a. outcomes b. treatment decisions c. prognostic risk factors based on diagnosis XIX. LeVeen Shunt A. Indications B. Radiopharmaceuticals 1. Tracers a. Tc-99m MAA b. Tc-99m sulfur colloid 2. Physical and chemical characteristics 3. Kit and radio pharmaceuticals 4. Dose range and route of administration 5. Biorouting a. uptake b. distribution c. excretion 6. Dosimtery C. Contraindications and adverse reactions 1. Physical and pathologic conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Special radiation safety considerations E. Patient preparation F. Equipment 1. camera 2. collimators 3. computer G. Basic procedure and processing 1. Protocols 2. Dose range and administration technique 3. Acquisition parameters 4. Positioning and views, including adaptations 5. Data processing 6. Image formatting 7. Pitfalls H. Interpretation of images and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic risk factors based on diagnosis a. outcomes b. treatment decisions c. prognostic risk factors based on diagnosis XX. Intahepatic pump study A. Indications B. Radiopharmaceuticals 1. Tracers a. Tc-99m MAA b. Tc-99m sulfur colloid 2. Physical and chemical characteristics 3. Kit and radio pharmaceuticals 4. Dose range and route of administration 5. Biorouting a. uptake b. istribution c. excretion 6. Dosimtery C. Contraindications and adverse reactions 1. Interfering studies 2. Precautions 3. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and processing 1. Protocols 2. Dose range and administration technique 3. Acquisition parameters 4. Positioning and views, including adaptations 5. Image formatting 6. Pitfalls G. Interpretation of images and data 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic risk factors based on diagnosis a. outcomes b. treatment decisions c. prognostic risk factors based on diagnosis XXI. Hematological and In Vitro Procedures - Review of anatomy and physiology A. Gross anatomy and function B. Cellular anatomy and function C. Life cycle of red and white blood cells D. Vitamin B12 absorption and biorouting XXII. Review of Hematological Pathology A. Anemias relevant to nuclear medicine studies 1. Pernicious anemia 2. Megaloblastic anemia (B12 or folic acid deficiency) 3. Thalassemia 4. Sickle cell anemia 5. Autoimmune hemolytic anemia 6. Traumatic cardiac hemolytic anemia 7. Hypersplenism B. Malabsorption syndrome C. Polycythemia vera D. Bone marrow cancers E. Bone marrow necrosis and infarct XXIII. Bone Marrow Imaging A. Indications B. Radiopharmaceutical 1. Tc-99m sulfur colloid 2. Physical and chemical characteristics 3. Kit and radiopharmaceutical preparation 4. Dose range and route of administration 5. Biorouting a. uptake b. distribution c. excretion 6. Dosimetry C. Contraindications and adverse reactions 1. Physical conditions 2. Interfering studies 3. Precautions 4. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and processing 1. Protocols 2. Dose range and administration technique 3. Acquisition parameters 4. Positioning and views, including adaptations 5. Image formatting 6. Pitfalls G. Interpretation of images 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors based on diagnosis XXIV. Schilling Test A. Indications B. Pharmaceuticals 1. Tracers a. Coblat-57 (Co-57) labeled B12 b. Co-58 labeled B12 2. Nonradioactive components a. Vitamin B12 b. Intrinsic factor 3. Physical and chemical characteristics 4. Radiopharmaceutical preparation 5. Dose range and route of administration 6. Biorouting a. uptake b. distribution c. excretion 7. Dosimetry C. Contraindications and adverse reactions 1. Physical and pathologic conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment F. Basic procedure and processing 1. Protocols 2. Dose range and administration technique 3. Data processing 4. Pitfalls G. Interpretation of data 1. Normal range 2. Normal variants 3. Abnormal 4. Sources of error 5. Diagnostic/Prognostic Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors based on diagnosis XXV. Plasma volume A. General principles of dilution tests 1. preparing standard solutions (dilutions) 2. dilution principle applied to blood volumes B. Indications C. Radiopharmaceuticals 1. I-125 RISA (radioiodinated serum albumin) 2. Physical and chemical characteristics 3. Standard and radiopharmaceutical preparation 4. Dose range and route of administration 5. Biorouting a. distribution b. excretion 6. Dosimetry D. Contraindications and adverse reactions 1. Physical and pathologic conditions 2. Interfering studies 3. Precautions 4. Adverse reactions E. Patient preparation F. Equipment G. Basic procedure and processing 1. Protocols 2. Dose range and administration technique 3. Data processing 4. Pitfalls H. Interpretation of data 1. Normal range calculations 2. Normal variants 3. Abnormal 4. Sources of error 5. Diagnostic/Prognostic Value of Study a. outcomes b. treatment decisions c. prognostic risk factors based on diagnosis XXVI. Red cell mass A. Indications B. Radiopharmaceuticals 1. Chromium-51 (Cr-51) sodium chromate tagged red blood cells 2. Physical and chemical characteristics 3. Standard and radiopharmaceutical preparation 4. Dose range and route of administration 5. Biorouting a. distribution b. excretion 6. Dosimetry C. Contraindications and adverse reactions 1. Physical and pathologic conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment F. Basic procedure and processing 1. Protocols 2. Dose range and administration technique 3. Data processing 4. Pitfalls G. Interpretation of data 1. Normal range calculations 2. Normal variants 3. Abnormal 4. Sources of error 5. Diagnostic/Prognostic Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors based on diagnosis XXVII. Total blood volume A. Indications B. Calculation from plasma volume and red cell mass C. Interpretation of data 1. Normal range calculations 2. Normal variant 3. Abnormal 4. Sources of error 5. Diagnostic/Prognostic Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors based on diagnosis XXVIII. Red cell survival and sequestration A. Indications B. Radiopharmaceuticals 1. Cr-51 sodium chromate tagged red blood cells 2. Physical and chemical characteristics 3. Standard and radiopharmaceutical preparation 4. Dose range and route of administration 5. Biorouting a. uptake b. distribution c. excretion 6. Dosimetry C. Contraindications and adverse reactions 1. Physical and pathologic conditions 2. Interfering studies 3. Interfering drugs 4. Precautions 5. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimator 3. computer 4. uptake probe F. Basic procedure and processing 1. Protocols 2. Dose range and administration technique 3. Data processing 4. Pitfalls G. Interpretation of data 1. Normal value 2. Normal variants 3. Abnormal 4. Sources of error 5. Diagnostic/Prognostic Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors based on diagnosis XXIX. Selective spleen imaging A. Indications B. Radiopharmaceuticals 1. denatured Cr-51 tagged red blood cells 2. Physical and chemical characteristics 3. Radiopharmaceutical preparation 4. Dose range and route of administration 5. Biorouting a. uptake b. distribution c. excretion 6. Dosimetry C. Contraindications and adverse reactions 1. Physical and pathologic conditions 2. Interfering studies 3. Precautions 4. Adverse reactions D. Patient preparation E. Equipment 1. camera 2. collimators 3. computer F. Basic procedure and processing 1. Protocol 2. Dose range and administration technique 3. Acquisition parameters 4. Positioning and views, including adaptations 5. Image formatting 6. Pitfalls G. Interpretation of images 1. Normal 2. Normal variants 3. Abnormal 4. Artifacts 5. Diagnostic/Prognostic Value of the Study a. outcomes b. treatment decisions c. prognostic risk factors based on diagnosis XXX. Radioassay A. Basic description and historical aspects B. Antibody productions C. Competitive assay 1. Types 2. Reagents 3. Basic method a. Procedure b. Law of mass action c. Equilibrium 4. Data reduction 5. Examples D. Direct or sandwich method 1. Reagents 2. Basic method a. Procedure b. Sequential saturation 3. Data reduction 4. Examples E. Quality control 1. Controls 2. Curve analysis 3. Statistical analysis a. Standard deviation b. Coefficient of variation c. Levy-Jennings graphs

Go to Description    Go to top of Competencies    Go to top of Outline